News

Core Essence Orthopaedics, a medical device company, has received 510k regulatory approval from the FDA for Securus, a novel knotless suture anchor system used in minimally invasive, arthroscopic

Azur will market Elestrin to estrogen prescribing physicians, comprised mostly of gynecologists. Azur recently increased its women’s health and urology sales force to 65 people to support the

The study has commenced recruiting patients in the US with sites in the UK, Germany and Australia due to open later in 2009. The OPTiM trial is a

Cardiometabolic Support Network, a team of medical experts, has adopted Cisco WebEx online meetings to deliver advice and support to patients through live, online group meetings with registered

“We are happy to report another quarter of excellent results and a very strong year filled with many accomplishments. We achieved record financial performance in 2008 with significant

The significant growth in revenues was due to an increase in sales of existing products in the growing China healthcare market, which included AMDL’s best-selling human placenta extract

Diluted earnings per share, excluding specified items, were $0.73, reflecting 15.9% growth, and $0.03 above the mid-point of Abbott’s previous first-quarter guidance range. Diluted earnings per share under

Biomerica reported operating income from continued operations for the quarter ended February 28, 2009 of $214,101 compared to operating income from continued operations of $118,009 in the year-ago

Daiichi Sankyo Company has filed patent infringement litigations against 11 generics companies for the substance patent and usage patent for levofloxacin hydrate. Daiichi Sankyo brought patent infringement actions